title: Reports to FDA of fatal anaphylaxis associated with intravenous iron products.
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Lynda
authors: L
authors: McCulley
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Kate
authors: K
authors: Gelperin
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Steven
authors: S
authors: Bird
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Sarah
authors: S
authors: Harris
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Cunlin
authors: C
authors: Wang
authors: U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Office of Pharmacovigilance and Epidemiology, Silver Spring, Maryland.
authors: Peter
authors: P
authors: Waldron
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000707:Anaphylaxis / Q000209:etiology* / Q000401:mortality; D017277:Drug Approval / Q000379:methods*; D005260:Female; D006801:Humans; D007501:Iron / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D014481:United States; D055815:Young Adult
chemical_list: D007501:Iron